Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 3Phase 1 3

Status

Recruiting 4Suspended 1

Sponsor Class

OTHER 3NIH 2

Study Type

Interventional 5

Sponsor

Cancer Type

NET 2Endocrine 2Genitourinary 1CNS 1Breast 1

Conditions

Prostatic Neoplasms 1Neuroendocrine Tumors 1Metastatic Digestive System Neuroendocrine Tumor G1 1Meningioma 1Disease Progression 1Breast Neoplasms 1

Interventions

Specimen Handling 128Magnetic Resonance Spectroscopy 105Biopsy 76pembrolizumab 63Nivolumab 60Carboplatin 59Cisplatin 57Cyclophosphamide 53Paclitaxel 44Radiotherapy 36Bevacizumab 36Gemcitabine 34Dexamethasone 33Rituximab 26Doxorubicin 26olaparib 25Pemetrexed 25Fluorouracil 25atezolizumab 24Radiation 24Injections 23Docetaxel 23fludarabine 22durvalumab 22Vincristine 21Prednisone 21Oxaliplatin 21Ipilimumab 21Cytarabine 21venetoclax 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × lutetium Lu 177 dotatate × 30 days × Clear all
NCT04529044 2026-06-05

177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer

OHSU Knight Cancer Institute

Phase 2 Recruiting
10 enrolled
Breast

Breast Neoplasms

NCT04954820 2026-06-04

ReLUTH

Institut du Cancer de Montpellier - Val d'Aurelle

Phase 2 Recruiting
146 enrolled
EndocrineNET

Neuroendocrine Tumors, Disease Progression

NCT05773274 2026-06-03

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
100 enrolled
EndocrineNET

Metastatic Digestive System Neuroendocrine Tumor G1

NCT05691465 2026-05-27

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

National Cancer Institute (NCI)

Phase 2 Recruiting
30 enrolled
Genitourinary

Prostatic Neoplasms

NCT06955169 2026-05-22

MOMENTUM-1

RTOG Foundation, Inc.

Phase 2 Suspended
153 enrolled
CNS

Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡